History, symptoms, and physical risk
Expect questions about cardiovascular health, neurological conditions, liver or kidney concerns, seizure history, current symptoms, prior adverse reactions, and other diagnoses that could alter acute risk.
A careful pre-decision guide
Safety & Screening
Before comparing ibogaine and ayahuasca, ask a more basic question: what information would need to be known to judge whether either option presents avoidable risk?
This page is informational only, not medical advice. Individual risk assessment belongs with licensed clinicians.
Screening comes before preference.
Ibogaine and ayahuasca involve different acute risks, different interaction concerns, and different questions about setting. A comparison is incomplete when it begins with hoped-for outcomes and ends before medical, psychiatric, medication, and emergency-readiness questions are answered.
For adults, families, and care-seeking professionals, the broader comparison framework for ibogaine and ayahuasca is most useful when safety information can change the decision—not merely decorate it.
A minimum screening framework
A credible process should make room for incomplete information, ask for records where needed, and be willing to conclude that a person should not proceed. These are distinct layers of review, not boxes to check after a decision has already been made.
Stability is not a minor detail
Screening should address current suicidality, prior psychosis or mania, bipolar-spectrum history, trauma-related vulnerability, recent crises, and whether there is reliable support before and after any experience.
A complete interaction review
Prescriptions, over-the-counter medicines, supplements, and substances all matter. A review should be done with a licensed clinician; no one should independently stop or change prescribed medication to qualify for a program.
Ibogaine: cardiac history and ECG review are central
Ibogaine deserves particular caution because cardiac risk is a central concern. A meaningful evaluation should ask about personal and family cardiac history, fainting, palpitations, prior arrhythmias, and all medicines or substances that may affect cardiac rhythm. An ECG is not a ceremonial formality: it should be obtained and interpreted by an appropriately qualified clinician as part of an individual assessment.
The U.S. National Library of Medicine describes electrocardiograms as tests that record the heart’s electrical activity; that is relevant because rhythm abnormalities can require clinical attention even when a person feels well. A program that cannot explain who reviews an ECG, how concerning findings are handled, and what would disqualify someone should not be treated as providing a robust medical screen.
Risk is not settled by a single normal result. Dehydration, electrolyte disturbance, recent substance use, medication changes, and the quality of monitoring can all affect the picture. People considering ibogaine in the context of neurological history may also find the material at ibogaine and brain injury questions useful for identifying uncertainties that need qualified clinical review.
Ayahuasca: MAOI contraindications and interaction review
Ayahuasca preparations commonly involve compounds with monoamine oxidase inhibitor activity. That makes a complete medication and substance review essential, not optional. Interaction concerns can include prescribed psychiatric medicines, stimulants, certain pain medicines, cough and cold products, supplements, and other substances.
The clinical overview of monoamine oxidase inhibitors explains why these medicines require careful attention to interactions and contraindications. It is not a substitute for individualized advice, and it does not justify self-directed medication changes. A licensed prescriber or pharmacist who knows the person’s full history is the appropriate place to address those decisions.
“Natural” does not mean predictable, and a retreat’s preparation list is not a substitute for a clinician-led assessment of prescribed medication, medical history, and psychiatric risk.
Psychiatric screening, emergency planning, and aftercare
Psychiatric screening should be direct about current suicidal thinking, past psychosis, manic or hypomanic episodes, bipolar risk, recent hospitalization, acute grief or destabilization, and available support. A history does not automatically determine an outcome, but it can make unsupervised or weakly supervised settings inappropriate.
The National Institute of Mental Health outlines when urgent support is needed for suicidal crisis concerns. If risk is present now, immediate safety and licensed mental-health care take priority over pursuing a psychedelic experience.
Pregnancy, breastfeeding, and uncertainty about either should be treated as reasons not to proceed without specialist medical guidance. Age also matters: minors require safeguarding and clinical oversight that informal programs may not provide, while older adults may have medical or medication factors needing closer review.
Emergency readiness means more than having a phone nearby. It means defined escalation pathways, trained personnel, appropriate equipment, and a realistic route to urgent medical care.
Demand clear answers
Questions that should not be negotiable
What should an emergency-response protocol explain?
It should identify who is responsible, what medical support is available, how emergencies are recognized, when transfer is initiated, and how the setting reaches urgent care. Vague assurances of “safety” do not describe an actual response system.
How should aftercare be planned?
Aftercare should include a stable place to recover, support for sleep and daily functioning, a plan for distress or unexpected symptoms, and follow-up with qualified care when needed. The questions used to evaluate program quality can help keep those practical expectations visible before any commitment is made.
What if medical or psychiatric risks are present?
When risks, uncertainty, or medication complexity are present, consult licensed clinicians and consider regulated studies rather than retreats. The decision-support materials available here are intended to help organize questions, not to replace that evaluation.
A decision can be cautious, delayed, or declined.
A responsible comparison includes the possibility that neither option is appropriate now. Clear screening, honest uncertainty, and adequate follow-up are stronger safeguards than confidence alone.